LBP
Reaktivität: Human
WB, IHC (p)
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
ELISA ,LBP inhibition studies, Western Blot. inhibits binding of LPS to membrane bound CD14, (Inhibits LPS-binding (0.5 ug/ml) to CD14+CHO cells (2 x 106/ml) up to 1:1000, total inhibition 1:5 Binding titre at mouse LBP- ELISA: 1:50.000 Cross reacting with rat LBP
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Reconstitute with bidistilled water
Konzentration
1 mg/mL
Buffer
PBS, pH 7.17
Konservierungsmittel
Without preservative
Lagerung
-20 °C,-80 °C
Dziarski, Tapping, Tobias: "Binding of bacterial peptidoglycan to CD14." in: The Journal of biological chemistry, Vol. 273, Issue 15, pp. 8680-90, (1998) (PubMed).
Weidemann, Schletter, Dziarski, Kusumoto, Stelter, Rietschel, Flad, Ulmer: "Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes." in: Infection and immunity, Vol. 65, Issue 3, pp. 858-64, (1997) (PubMed).
Target
LBP
(Lipopolysaccharide Binding Protein (LBP))
Andere Bezeichnung
Lipopolysaccharide (LPS)-Binding Protein (LBP) (LBP Produkte)
Background: Natural LBP is a 58KD glycoprotein produced in liver. It binds at lipid A of LPS with high affinity (10-9M) and reduced the cellular LPS effects at CD14+ cells (IL1ß, IL6, TNFα). It acts as opsonin for GRAM negative cells, LPS, neutrophiles and granulocytes.